Fisher Asset Management LLC Has $1.43 Billion Stock Position in Abbott Laboratories $ABT

Posted by Brian Himes on May 25th, 2026

Fisher Asset Management LLC lowered its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 4.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 11,440,255 shares of the healthcare product maker’s stock after selling 592,629 shares during the period. Fisher Asset Management LLC’s holdings in Abbott Laboratories were worth $1,433,350,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of Abbott Laboratories by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after purchasing an additional 2,402,408 shares during the period. Capital International Investors lifted its stake in shares of Abbott Laboratories by 2.5% in the 3rd quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock valued at $8,251,974,000 after purchasing an additional 1,478,076 shares during the period. Invesco Ltd. lifted its stake in shares of Abbott Laboratories by 51.0% in the 3rd quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock valued at $1,868,718,000 after purchasing an additional 4,713,135 shares during the period. Ameriprise Financial Inc. lifted its stake in shares of Abbott Laboratories by 3.8% in the 3rd quarter. Ameriprise Financial Inc. now owns 13,500,829 shares of the healthcare product maker’s stock valued at $1,804,050,000 after purchasing an additional 499,351 shares during the period. Finally, Legal & General Group Plc lifted its stake in shares of Abbott Laboratories by 7.2% in the 3rd quarter. Legal & General Group Plc now owns 12,900,318 shares of the healthcare product maker’s stock valued at $1,727,869,000 after purchasing an additional 864,531 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on ABT. TD Cowen dropped their price objective on Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. BTIG Research reaffirmed a “buy” rating and set a $131.00 price objective on shares of Abbott Laboratories in a research note on Monday, April 27th. Evercore dropped their price objective on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Raymond James Financial dropped their price objective on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Finally, UBS Group dropped their price objective on Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $119.43.

Check Out Our Latest Analysis on Abbott Laboratories

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: A TipRanks roundup highlighted Abbott as one of three “Strong Buy” dividend aristocrat stocks with more than 15% upside potential, which may support investor confidence in the name. 3 ‘Strong Buy’ Dividend Aristocrat Stocks with 15%+ Upside, 5/22/26
Positive Sentiment: Another piece argued that Abbott’s Lingo wearable and increased cardiovascular R&D could strengthen its long-term growth outlook by expanding its health-tech and diagnostics footprint. Abbott’s Lingo Wearable And Cardio R&D Reframe Long Term Growth Story
Neutral Sentiment: One market note said traders are waiting for more clarity on integration results, suggesting investors are in a “show-me” phase rather than fully repricing the stock higher. Waiting on Integration Result, Market Stays Moderated on Abbott Laboratories (ABT)
Negative Sentiment: Another article said Abbott has been “slid” in part because its nutrition segment is sensitive to consumer spending trends, highlighting macro pressure on a key business line. Abbott Laboratories (ABT) Slid Due To Its Nutrition Segment’s Sensitivity to Consumer Spending Momentum
Negative Sentiment: Goldman Sachs reportedly removed Abbott from its U.S. Conviction List, which may weigh on sentiment even though it does not change the company’s fundamentals. Why UnitedHealth (UNH) Remains a Turnaround Bet Despite Policy and Cost Pressure

Abbott Laboratories Price Performance

ABT stock opened at $87.42 on Monday. The stock has a 50-day moving average price of $96.74 and a two-hundred day moving average price of $111.97. The stock has a market cap of $152.27 billion, a PE ratio of 24.49, a price-to-earnings-growth ratio of 1.46 and a beta of 0.65. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $139.06.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company’s revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Insider Activity

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the transaction, the executive vice president owned 146,377 shares in the company, valued at approximately $16,918,253.66. This represents a 0.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Philip P. Boudreau bought 2,200 shares of the stock in a transaction on Thursday, April 23rd. The shares were purchased at an average price of $91.50 per share, with a total value of $201,300.00. Following the acquisition, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.